Overexpression of Fas ligand does not confer immune privilege to a pancreatic β tumor cell line (βTC-3)

被引:11
|
作者
Okamoto, S
Takamizawa, S
Bishop, W
Wen, J
Kimura, K
Sandler, A
机构
[1] Univ Iowa Hosp & Clin, Dept Surg, Iowa City, IA 52242 USA
[2] Univ Iowa, Dept Surg, Iowa City, IA 52242 USA
[3] Univ Iowa, Dept Pediat, Iowa City, IA 52242 USA
关键词
Fas ligand; immune privilege; beta tumor cell line;
D O I
10.1006/jsre.1999.5613
中图分类号
R61 [外科手术学];
学科分类号
摘要
Background. Fas ligand (Fas-L) is thought to provide immune privilege to specific tissues and tumors by inducing an apoptotic signal of cytotoxic T cells expressing its Fas receptor. Purpose. The purpose of this work was to evaluate whether an immortalized insulin-secreting cell line (beta TC-S) gains immune privilege by inducing overexpression of Fas-L. Methods. A lipofection technique was used to transfect a beta TC-3 tumor cell line with a plasmid (pcDNA3.1/Zee) carrying the Fas-L gene and a zeocin resistance gene. Insertion of Fas-L into PTC was characterized by reverse transcription polymerase chain reaction (RT-PCR) and the ability of transfectants (beta TC-3/Fas-L) to induce apoptosis of Fas-sensitive T cells. Transfectants and control cells were tested for insulin secretion following which 1 x 10(6) insulin-secreting beta TC-3 and beta TC-3/Fas-L cells were subcutaneously implanted into syngeneic, allogeneic, and Fas mutant (Ipr) syngeneic mice. Survival of the insulin-secreting cells was then determined by monitoring serum glucose levels in recipients. Results. Successful transfection of vector resistance gene was achieved in the transfected beta TC-3 cells, which was confirmed by zeocin resistance. BT-PCR in resistant Fas-L clones confirmed the transcription of Fas-L, which was absent in controls. Fas-L transfectants induced 20 +/- 4.2% apoptosis of Fas-sensitive T cells, while controls induced 3.47 +/- 2.3% by flow cytometry (P = 0.04, n = 3). Insulin secretion was equivalent in both beta TC-3 and beta TC-3/Fas-L cells. Syngeneic mice implanted with control beta TC-3 cells died within 3 weeks from hypoglycemia due to overgrowth of beta TC-3 tumor. Implanted Fas-L transfected beta TC-3 cells were killed and had no effect on glycemic status except in Fas mutant hosts, where tumors formed in two of three mice. Conclusions. Despite the ability of transfected beta TC-3 cells to induce apoptosis of T cells in vitro, expression of Fas-L provided no immune privilege to these cells in vivo but paradoxically induced killing of beta TC-3 cells even in syngeneic hosts. (C) 1999 Academic Press.
引用
收藏
页码:77 / 81
页数:5
相关论文
共 50 条
  • [1] Fas ligand expression in islets of Langerhans does not confer immune privilege and instead targets them for rapid destruction
    Kang, SM
    Schneider, DB
    Lin, ZH
    Hanahan, D
    Dichek, DA
    Stock, PG
    Baekkeskov, S
    NATURE MEDICINE, 1997, 3 (07) : 738 - 743
  • [2] Fas ligand expression in islets of Langerhans does not confer immune privilege and instead targets them for rapid destruction
    Sang-Mo Kang
    Darren B. Schneider
    Zhonghua Lin
    Douglas Hanahan
    David A. Dichek
    Peter G. Stock
    Steinunn Baekkeskov
    Nature Medicine, 1997, 3 : 738 - 743
  • [4] Expression of human Fas ligand on mouse beta islet cells does not induce insulitis but is insufficient to confer immune privilege for islet grafts
    Hsu, PN
    Lin, HH
    Tu, CF
    Chen, NJ
    Wu, KM
    Tsai, HF
    Hsieh, SL
    JOURNAL OF BIOMEDICAL SCIENCE, 2001, 8 (03) : 262 - 269
  • [5] Fas ligand expression in colon cancer: A possible mechanism of tumor immune privilege
    Zhang, Wei
    Ding, Er-Xun
    Wang, Qiang
    Zhu, Da-Qiao
    He, Jin
    Li, Yu-Li
    Wang, Yuan-He
    WORLD JOURNAL OF GASTROENTEROLOGY, 2005, 11 (23) : 3632 - 3635
  • [6] A vision of cell death: Fas ligand and immune privilege 10 years later
    Ferguson, Thomas A.
    Griffith, Thomas S.
    IMMUNOLOGICAL REVIEWS, 2006, 213 : 228 - 238
  • [7] Activation-induced cell death: The controversial role of Fas and Fas ligand in immune privilege and tumour counterattack
    Maher, S
    Toomey, D
    Condron, C
    Bouchier-Hayes, D
    IMMUNOLOGY AND CELL BIOLOGY, 2002, 80 (02): : 131 - 137
  • [8] Fas (CD95/APO-1) and Fas ligand expression in normal pancreas and pancreatic tumors - Implications for immune privilege and immune escape
    Bernstorff, WV
    Glickman, JN
    Odze, RD
    Farraye, FA
    Joo, HG
    Goedegebuure, PS
    Eberlein, TJ
    CANCER, 2002, 94 (10) : 2552 - 2560
  • [9] Immune privilege sites require a higher threshold level of membrane Fas ligand to stimulate inflammation and tumor rejection
    Gregory, MS
    Repp, A
    Hohlbaum, A
    Saff, R
    Marshak-Rothstein, A
    Ksander, B
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2002, 43 : U449 - U449
  • [10] Overexpression of fas-ligand by neuroblastoma: A novel mechanism of tumor-cell killing
    Takamizawa, S
    Okamoto, S
    Wen, J
    Bishop, W
    Kimura, K
    Sandler, A
    JOURNAL OF PEDIATRIC SURGERY, 2000, 35 (02) : 375 - 379